NL9400309A - Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26. - Google Patents

Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26. Download PDF

Info

Publication number
NL9400309A
NL9400309A NL9400309A NL9400309A NL9400309A NL 9400309 A NL9400309 A NL 9400309A NL 9400309 A NL9400309 A NL 9400309A NL 9400309 A NL9400309 A NL 9400309A NL 9400309 A NL9400309 A NL 9400309A
Authority
NL
Netherlands
Prior art keywords
ada
cells
ligand according
monoclonal antibody
ligand
Prior art date
Application number
NL9400309A
Other languages
English (en)
Dutch (nl)
Original Assignee
Eurogenetics Nv
Universitaire Instelling Antwe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurogenetics Nv, Universitaire Instelling Antwe filed Critical Eurogenetics Nv
Priority to PT95900671T priority Critical patent/PT726915E/pt
Priority to PCT/EP1994/003632 priority patent/WO1995012618A1/en
Priority to EP95900671A priority patent/EP0726915B1/de
Priority to DK95900671T priority patent/DK0726915T3/da
Priority to EP01203730A priority patent/EP1179542A1/de
Priority to AU81404/94A priority patent/AU8140494A/en
Priority to DE69431526T priority patent/DE69431526T2/de
Priority to AT95900671T priority patent/ATE225808T1/de
Priority to ES95900671T priority patent/ES2180619T3/es
Publication of NL9400309A publication Critical patent/NL9400309A/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
NL9400309A 1993-11-04 1994-02-28 Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26. NL9400309A (nl)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PT95900671T PT726915E (pt) 1993-11-04 1994-11-04 Ligando capaz de se ligar ao local de ligacao da adenosina-desaminase do cd26
PCT/EP1994/003632 WO1995012618A1 (en) 1993-11-04 1994-11-04 A ligand capable of binding to the adenosine deaminase binding-site of cd26
EP95900671A EP0726915B1 (de) 1993-11-04 1994-11-04 Ligand fähig zur bindung an der adenosinedeaminase-bindungsstelle von cd26
DK95900671T DK0726915T3 (da) 1993-11-04 1994-11-04 Ligand, som er i stand til binding af adenosindeaminasebindingsstedet CD26
EP01203730A EP1179542A1 (de) 1993-11-04 1994-11-04 Ligand fähig zur Bindung an der Adenosinedeaminase-Bindungsstelle von CD26
AU81404/94A AU8140494A (en) 1993-11-04 1994-11-04 A ligand capable of binding to the adenosine deaminase binding-site of cd26
DE69431526T DE69431526T2 (de) 1993-11-04 1994-11-04 Ligand fähig zur bindung an der adenosinedeaminase-bindungsstelle von cd26
AT95900671T ATE225808T1 (de) 1993-11-04 1994-11-04 Ligand fähig zur bindung an der adenosinedeaminase-bindungsstelle von cd26
ES95900671T ES2180619T3 (es) 1993-11-04 1994-11-04 Un ligando capaz de unirse al sitio de union de la adenosina-desaminasa de cd26.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93203093 1993-11-04
EP93203093 1993-11-04

Publications (1)

Publication Number Publication Date
NL9400309A true NL9400309A (nl) 1995-06-01

Family

ID=8214159

Family Applications (1)

Application Number Title Priority Date Filing Date
NL9400309A NL9400309A (nl) 1993-11-04 1994-02-28 Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26.

Country Status (9)

Country Link
EP (2) EP1179542A1 (de)
AT (1) ATE225808T1 (de)
AU (1) AU8140494A (de)
DE (1) DE69431526T2 (de)
DK (1) DK0726915T3 (de)
ES (1) ES2180619T3 (de)
NL (1) NL9400309A (de)
PT (1) PT726915E (de)
WO (1) WO1995012618A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
AU6280296A (en) * 1995-06-16 1997-01-15 Enzon, Inc. Method of treating cd4+ t cell lymphopenia in immuno-compromised patients
US5728560A (en) * 1996-06-14 1998-03-17 Enzon, Inc. Method of treating CD4+ T cell lymphopenia in immuno-compromised patients
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6040145A (en) 1997-05-07 2000-03-21 Tufts University Potentiation of the immune response
US6100234A (en) 1997-05-07 2000-08-08 Tufts University Treatment of HIV
CA2304206A1 (en) 1997-09-29 1999-04-08 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
CA2331122A1 (en) 1998-05-04 1999-11-11 Point Therapeutics, Inc. Hematopoietic stimulation
AU765370B2 (en) 1998-06-05 2003-09-18 Point Therapeutics, Inc. Cyclic boroproline compounds
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US11242399B2 (en) 2013-02-19 2022-02-08 Adienne S.A. Anti-CD26 antibodies
EP2767549A1 (de) * 2013-02-19 2014-08-20 Adienne S.A. Anti-CD26-Antikörper und Verwendungen davon
TWI677505B (zh) * 2014-08-18 2019-11-21 瑞士商艾迪安納股份有限公司 抗ｃｄ２６抗體及其用途

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. ULMER ET AL.: "CD26 antigen is a surface dipeptidylpeptidase IV (DPPIV) as characterized by monoclonal antibodies clone TII-19-4-7 and 4EL1C7.", THE SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 31, no. 4, April 1990 (1990-04-01), OXFORD, GROOT BRITTANNIE, pages 429 - 435 *
I. DE MEESTER ET AL.: "Antibody binding profile of purified and cell-bound CD26. Designation of BT5/9 and TA5.9 to the CD26 cluster.", IMMUNOBIOLOGY, vol. 188, no. 1-2, June 1993 (1993-06-01), STUTTGART, DUITSLAND, pages 145 - 158 *
I. DE MEESTER ET AL.: "Down-regulation of CD26 surface expression by anti-TA5.9 monoclonal antibody.", TISSUE ANTIGENS, vol. 42, no. 4, 1993, KOPENHAGEN, DENEMARKEN, pages 242 *
M. MORRISON ET AL.: "A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase.", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 177, no. 4, 1 April 1993 (1993-04-01), NEW YORK NY, VERENIGDE STATEN VAN AMERICA, pages 1135 - 1143 *
Y. TORIMOTO ET AL.: "Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies.", MOLECULAR IMMUNOLOGY, vol. 29, no. 2, February 1992 (1992-02-01), OXFORD, GROOT BRITTANNIE, pages 183 - 192 *

Also Published As

Publication number Publication date
EP1179542A1 (de) 2002-02-13
WO1995012618A1 (en) 1995-05-11
DE69431526T2 (de) 2003-07-10
EP0726915A1 (de) 1996-08-21
EP0726915B1 (de) 2002-10-09
DE69431526D1 (de) 2002-11-14
ES2180619T3 (es) 2003-02-16
AU8140494A (en) 1995-05-23
PT726915E (pt) 2003-02-28
ATE225808T1 (de) 2002-10-15
DK0726915T3 (da) 2003-02-17

Similar Documents

Publication Publication Date Title
Dianzani et al. Molecular associations on the T cell surface correlate with immunological memory
Baetz et al. Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis.
US6010902A (en) Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
Bednarczyk et al. Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation
Gavioli et al. CD69 molecule in human neutrophils: its expression and role in signal-transducing mechanisms
AU629204B2 (en) Novel antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
NL9400309A (nl) Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26.
Mittler et al. Physical associations between CD45 and CD4 or CD8 occur as late activation events in antigen receptor-stimulated human T cells
JP2014525940A (ja) インスリン様成長因子１による細胞の活性化を阻害するための方法
JPS6410000B2 (de)
Vasu et al. Targeted engagement of CTLA‐4 prevents autoimmune thyroiditis
Yuti et al. Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition
EP1013668A1 (de) Monoklonaler antikörper gegen humane monozyten
US5252556A (en) Fragment capable of binding anti-CD43 autoantibodies
Goldman et al. Differential activation of phosphotyrosine protein phosphatase activity in a murine T cell hybridoma by monoclonal antibodies to CD45.
AU766882B2 (en) Product and method for treatment of conditions associated with receptor-desensitization
Avrameas et al. A quantitative study at the single cell level of immunoglobulin antigenic determinants present on the surface of murine B and T lymphocytes
Ikewaki et al. Development and characterization of a novel monoclonal antibody (mNI‐11) that induces cell adhesion of the LPS‐stimulated human monocyte‐like cell line U937
US4816404A (en) Late differentiation antigens associated with helper T lymphocyte function
LaMantia et al. Lymphocyte 5’-nucleotidase: Absence of detectable protein in chronic lymphocytic leukemia
JP4826697B2 (ja) 個別化抗ガン抗体
de Meester et al. Antibody binding profile of purified and cell-bound CD26. Designation of BT5/9 and TA5. 9 to the CD26 cluster
JP2003515535A (ja) 腫瘍関連抗原発現を調節するための組成物および方法
Frensch et al. Bacterial lectin BambL acts as a B cell superantigen
US8080242B2 (en) Anti-HPA

Legal Events

Date Code Title Description
A1B A search report has been drawn up
BC A request for examination has been filed
BN A decision not to publish the application has become irrevocable